Navigation Links
Safety Of Heart Drug Questioned

Reports of increased incidence of kidney failure following use of the drug aprotinin, marketed as Trasylol, has prompted necessity for reconsidering the use of the drug in heart surgery patients.// The clotting drug is commonly used to prevent excessive bleeding in patients undergoing cardiac surgery.

It has now been found from the present study that Trasylol injected patients were twice as likely to develop kidney failure and suffer from heart disorders compared to controls who received other drugs. The results of the study can be found in the New England Journal of Medicine.

The U.S. Food and Drug Administration (FDA) approved the drug for use in 1993. The primary indication was to control the bleeding and reduce necessity of blood transfusion in patients who underwent open-heart surgery. The drug acts by blocking the function of enzymes that are involved in the clot dissolving process.

The drug manufacturer, Bayer AG, a German based concern in response has stated that the drug has been approved following demonstration of adequate safety level in trials conducted by the company itself. Drug regulatory boards in Canada, Europe, Australia and United States have been alerted regarding the above research.

Last week, concerns were raised regarding the use of Novoseven, a drug used for management of cerebral hemorrhages (primary indication is for treatment of hemophilia). Increased risk of heart attack, stroke and even death were reported with use of the drug.

The researchers examined the effect of Trasylol in nearly 4,374 cardiac surgery patients. The study participants were given either Trasylol or a placebo. At the end of the study, the incidence of kidney failure, requiring dialysis was twice as likely in patients who took Trasylol when compared to the control group. The risk of heart attack or heart failure was 55% greater amongst Trasylol users.

Although anesthesiologists and surge ons have been raising concerns regarding the use of the drug, it is for the first time that a comprehensive study regarding safety of Trasylol has been conducted. More studies are clearly indicated in the future to accurately predict the risk-benefit ratio of such dangerous blood-thinning drugs.


Related medicine news :

1. New standards for Human Research Safety
2. Safety of soy under suspicion
3. The Safety Of Prenatal Ultrasounds Questioned
4. Report on the Safety and Effectiveness of Melatonin supplements
5. Monitoring Drug Safety
6. Safety Of Indian Sex Workers At Risk Due To Poor Condom Usage
7. Race Was Used To Determine Safety Of Blood
8. Patient Safety Forces Closure Of Hospital
9. Farm Boy Airlifted by PSNI helicopter To Safety
10. Strict Safety Measures On Import of Poultry From China
11. Botox Treatment Now With A Lesser Dose And Increased Safety
Post Your Comments:

(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: